X
Search
X

Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.

X

Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

- test

CURE® Speaking Out Launches Video Series in Recognition of National Prostate Cancer Awareness Month

In support of National Prostate Cancer Awareness Month, the CURE® Speaking Out video series has revealed a five-episode discussion titled, “Discussing Trends... Read More

FDA Approves Clovis Oncology’s Rubraca For Prostate Cancer

BOULDER, Colo.–(BUSINESS WIRE)–Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that the U.S. Food and Drug Administration (FDA) approved Rubraca® (rucaparib) tablets... Read More

U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

Astellas Pharma Inc., and Pfizer Inc. today announced the FDS approved a supplemental New Drug Application for XTANDI®, based on... Read More

Results from Blue Earth Diagnostics’ LOCATE Trial Show 59% of Patients with Suspected Recurrent Prostate Cancer Had Change in Management Plan Following 18F Fluciclovine PET/CT Scan

Blue Earth Diagnostics, a molecular imaging diagnostics company, announced the topline results from an investigational clinical trial (“LOCATE”) evaluating the... Read More

Dendreon Initiates Large-Scale Clinical Trial to Investigate PROVENGE® (sipuleucel-T) in Men with Early-Stage Prostate Cancer on Active Surveillance

Dendreon Pharmaceuticals LLC, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, announced it will conduct a large-scale,... Read More

NanOlogy™ Announces First Patient Enrolled in a Phase 2 Clinical Trial of NanoPac® for Treatment of Prostate Cancer

NanOlogy LLC, a clinical-stage pharmaceutical development company, today announced the first patient has been enrolled in a clinical trial of... Read More

Augmenix Announces First Prostate Cancer Patients Treated with SpaceOAR:registered: Hydrogel in Israel

Augmenix, Inc., a medical technology company that develops, manufactures, and sells proprietary absorbable hydrogels that separate and protect organs at... Read More

Phase 3 Trial Data Show Use of SpaceOAR® Hydrogel Helps Maintain Erectile Function Following Prostate Cancer Radiation Treatment

Read more.

Minomic Announces Clinical Study Update for MILGa in Prostate, Bladder and Pancreatic Cancers

Minomic International Ltd (Minomic) is an immuno-oncology company specializing in therapeutics and diagnostics for solid tumors, including prostate, bladder and... Read More

First-Ever Crowdsourced Prostate Cancer Data-Mining Competition Discovery Impacts and Predicts Patient Survival

A breakthrough report in the international journal Lancet Oncology demonstrates how a collaborative effort to analyze broadly accessible clinical data... Read More